IN THE CLAIMS:

Claim 1 (previously presented) A cis-stilbene of the formula



wherein:

R^1, R^2 and R^3 are each independently alkyl,

R^4 is alkyl, haoloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo,

R^5 is hydrogen, alkoxy, alkyl, alkylthio, hydorxy or halo,

or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.

Claim 2 (Original) A cis-stilbene according to claim 1 wherein R^1, R^2 and R^3 are all methyl.

Claim 3 (Original) A cis-stilbene according to claim 1 wherein R^5 is hydrogen and R^4 is alkyl or halo.

Claim 4 (currently amended) (Z)-1-(3-~~htdroxy~~ hydroxyl-4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene.

Claim 5 (previously presented) A prodrug of a cis-stilbene which is a carboxylate ester,

phosphate ester, sulphate ester or carbonate of the cis-stilbene as claimed in claim 1.

Claim 6 (Original) A prodrug of a cis-stilbene which is a phosphate ester of a cis-stilbene according to claim 1.

Claim 7 (Original) A prodrug according to claim 5 which is a dihydrogen phosphate ester.

Claim 8 (currently amended) (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)~~ethynyl~~ ethenyl]phenyl dihydrogen phosphate.

Claim 9 (previously presented) A composition for use in the destruction of neovasculature which composition contains an amount of the cis-stilbene according to claim 1 effective to destroy neovasculature and a pharmaceutically acceptable excipient.

Claim 10 (withdrawn) A method for treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising the cis-stilbene as claimed in claim 1.

Claim 11 (previously presented) A prodrug of a cis-stilbene which is a carboxylate ester, phosphate ester, sulphate ester or carbonate of the cis-stilbene as claimed in claim 2.

Claim 12 (previously presented) A prodrug of a cis-stilbene which is a carboxylate ester, phosphate ester, sulphate ester or carbonate of the cis-stilbene as claimed in claim 3.

Claim 13 (previously presented) A composition for use in the destruction of neovasculature which composition contains an amount of the prodrug according to claim 5 effective to destroy neovasculature and a pharmaceutically acceptable excipient.

Claim 14 (withdrawn) A method for treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising the prodrug as claimed in claim 5.

Claims 15 - 17 ~~18~~ (cancelled)

Claim 18 (previously presented) A composition for use in the destruction of neovasculature which composition contains an amount of a compound according to claim 2 effective to destroy neovasculature and a pharmaceutically acceptable excipient.

Claim 19 (previously presented) A composition for use in the destruction of neovasculature which composition contains an amount of a compound according to claim 3 effective to destroy neovasculature and a pharmaceutically acceptable excipient.

Claim 20 (currently amended) A composition for use in the destruction of neovasculature which composition contains an amount of (Z)-1-(3-~~htdroxy~~ hydroxyl-4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene or a prodrug thereof effective to destroy neovasculature and a pharmaceutically acceptable excipient.

Claim 21 (previously presented) A cis-stilbene prodrug of formula



wherein:

R^1, R^2 and R^3 are each independently alkyl,

R^4 is alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo,

R^5 is hydrogen, alkoxy, alkyl, alkylthio, hydroxyl or halo, and

X is a group which can be removed in vivo by hydrolysis.

Claim 22 (previously presented) A cis-stilbene prodrug according to claim 21 wherein:

R^1, R^2 and R^3 are all methyl.

Claim 23 (previously presented) A cis-stilbene prodrug according to claim 22 wherein:

R^5 is hydrogen and R^4 is alkyl or halo.

Claim 24 (previously presented) A cis-stilbene prodrug according to claim 23 wherein R^4 is methyl.

Claim 25 (previously presented) A cis-stilbene prodrug according to claim 21 which is a

carboxylic ester, phosphate ester, sulphate ester or carbonate.

Claim 26 (previously presented) A cis-stilbene prodrug according to claim 21 which is a phosphate ester.

Claim 27 (previously presented) A prodrug according to claim 25 which is a dihydrogen phosphate ester.

Claim 28 (previously presented) (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate.

Claim 29 (previously presented) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 21 and a pharmaceutically acceptable excipient.

Claim 30 (previously presented) A composition as claimed in claim 29 in combination with at least one further anti-tumour substance.

Claim 31 (previously presented) A cis-stilbene prodrug according to claim 22 which is a carboxylic ester, phosphate ester, sulphate ester or carbonate.

Claim 32 (previously presented) A cis-stilbene prodrug according to claim 23 which is a carboxylic ester, phosphate ester, sulphate ester or carbonate.

Claim 33 (previously presented) A composition for use in the destruction of neovasculature which composition contains an effective amount of the prodrug according to claim 25 and a pharmaceutically acceptable excipient.

Claim 34 (previously presented) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 26 and a pharmaceutically acceptable excipient.

Claim 35 (previously presented) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 27 and a pharmaceutically acceptable excipient.

Claim 36 (previously presented) A composition for use in the destruction of neovasculature composition contains an effective amount of the cis-stilbene dihydrogen phosphate according to claim 28 and a pharmaceutically acceptable excipient.

Claim 37 (withdrawn) A method of treatment of a disease involving neovascularisation comprising the administration of an effective amount of a cis-stilbene prodrug as claimed in claim 21.

Claim 38 (withdrawn) A method according to claim 37 wherein the disease is cancer involving a solid tumour.

Claim 39 (withdrawn) A method according to claim 38 wherein said cis-stilbene prodrug is administered in combination with radiotherapy or another anti-tumor substance.

Claim 40 (withdrawn) A method according to claim 37 wherein the disease is a disease of the eye.

Claim 41 (withdrawn) A method according to claim 37 wherein the cis-stilbene prodrug is (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate.

Claim 42 (withdrawn) A method of treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising a compound according to claim 4.

Claim 43 (withdrawn) A method of treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising a dihydrogen phosphate ester of a compound according to claim 4.

Claim 44 (withdrawn) A method according to claim 42 wherein neovascularisation of the eye is treated.

Claim 45 (withdrawn) A method according to claim 43 wherein neovascularisation of the eye is treated.